Reticulin IgA Test

If you have unexplained digestive symptoms, a family member with celiac disease, type 1 diabetes, or a stubborn itchy rash that won't quit, this test can tell you whether your immune system is quietly attacking your gut in response to gluten. A positive result is rarely a coincidence.

Reticulin IgA (immunoglobulin A) is one of the oldest serologic markers for celiac disease. It is highly specific, meaning a positive result strongly points toward gluten-driven intestinal injury rather than another condition. It is most useful when read alongside newer, more sensitive tests.

What This Antibody Actually Is

Reticulin IgA is an autoantibody, an immune protein your body produces that mistakenly targets your own tissues. Specifically, it binds to reticulin, a network of thin fibers that forms the connective tissue scaffolding around organs like the gut, liver, kidney, and spleen. In people with celiac disease, eating gluten triggers the immune system to make these antibodies, and they travel in the bloodstream where a lab can detect them.

The target of this antibody overlaps closely with the target of another well-known celiac marker called endomysial antibody. In laboratory studies, researchers could not cleanly separate human-type reticulin antibodies from endomysial antibodies, suggesting they recognize very similar structures in the gut wall.

Why It Matters for Celiac Disease

In adults with untreated celiac disease, reticulin IgA is positive in about 91% of cases, with a specificity of 99%. That means if your result is positive, the chance it reflects real gluten-driven gut damage rather than a false alarm is very high. In children with active celiac disease, sensitivity is around 79% with 100% specificity.

The antibody behavior tracks closely with what is happening in your small intestine. When the lining of the gut (specifically, finger-like projections called villi) is flattened by gluten exposure, reticulin IgA is usually present. When you remove gluten from your diet and the gut heals, the antibody fades. Reintroduce gluten, and it comes back. This makes it both a diagnostic clue and a way to confirm whether a gluten-free diet is actually working.

Why It Matters for Dermatitis Herpetiformis

Dermatitis herpetiformis is the skin form of celiac disease, characterized by intensely itchy blisters, often on the elbows, knees, or buttocks. Between 68% and 93% of people with this skin condition have reticulin IgA antibodies, especially those who also have flattening of the gut lining. The antibody is a reliable indicator that the rash is gluten-driven and that the small intestine is involved, even when digestive symptoms are absent.

Why It Matters for At-Risk Groups

Some people are at much higher risk of celiac disease than the general population, and reticulin IgA can catch silent or latent cases before symptoms appear. In a study of children with type 1 diabetes, repeated annual testing detected new positive results in a subset of children, and several went on to develop biopsy-confirmed celiac disease, often without classic symptoms.

Among first-degree relatives of people with celiac disease, about 20% test positive for IgA reticulin antibodies. Many of these family members have flattened gut villi on biopsy despite feeling well. The takeaway: if a parent, sibling, or child has celiac disease, your standard checkup is not enough.

Reference Ranges

Reticulin IgA is a qualitative test in most labs, meaning the result is reported as positive, negative, or sometimes weakly positive, rather than as a number on a numeric scale. The cutoff for positivity depends on the assay method (most commonly indirect immunofluorescence), so results from different labs are not always directly comparable. Track results within the same lab over time for the most meaningful trend.

How It Compares to Newer Celiac Tests

Reticulin IgA is rarely used as a stand-alone test today. Two newer markers have largely replaced it as first-line tools: tissue transglutaminase IgA (tTG-IgA) and endomysial antibody IgA (EmA-IgA). Both are more sensitive than reticulin IgA, meaning they catch more cases of celiac disease, with similarly high specificity.

In head-to-head comparisons, endomysial IgA reaches 97% to 100% sensitivity and 98% to 99% specificity in active celiac disease, slightly outperforming reticulin IgA. Reticulin IgA remains useful as a confirmatory marker when positive, because its 99% to 100% specificity makes a positive result very meaningful. Many modern celiac panels include tTG-IgA and endomysial IgA but skip reticulin IgA entirely, which is one reason this test can fill an important gap when ordered intentionally.

Why a Single Reading Is Not Enough

A negative reticulin IgA does not rule out celiac disease, especially in high-risk groups. Some biopsy-confirmed celiac patients lack reticulin IgA but have IgG reticulin or endomysial antibodies. In family members of people with celiac disease and in children with type 1 diabetes, some individuals initially test negative but develop antibodies over months or years.

For these reasons, a single reading captures only a moment in time. If you are in a high-risk group (family history of celiac disease, type 1 diabetes, autoimmune thyroid disease), retest annually or every two years even if your first result is negative. If your first test is positive, retest after 6 to 12 months on a strict gluten-free diet to confirm the antibody is dropping, which signals dietary adherence and gut healing.

When Results Can Be Misleading

A few factors can produce a misleading reticulin IgA result. The most important is selective IgA deficiency, a condition where the body does not produce enough IgA antibodies overall. About 2% of people with celiac disease also have IgA deficiency, and in these individuals, all IgA-based celiac tests, including reticulin IgA, can appear falsely negative. Total serum IgA should be measured alongside this test to interpret a negative result correctly.

A gluten-free or low-gluten diet before testing can also lower the antibody, even in someone with true celiac disease. If you are considering testing, continue eating gluten regularly for at least several weeks beforehand, otherwise the test may miss the diagnosis. Immune checkpoint inhibitors, a class of cancer drugs, have been reported in case reports to trigger celiac disease, so a new positive result during cancer treatment warrants clinical correlation rather than dismissal.

What to Do With an Abnormal Result

A positive reticulin IgA is meaningful and should never be ignored. The next step is confirmatory testing with tissue transglutaminase IgA, endomysial IgA, total serum IgA (to rule out IgA deficiency), and ideally a referral to a gastroenterologist for upper endoscopy with small intestinal biopsy. The biopsy remains the gold standard for confirming celiac disease in adults.

Do not start a gluten-free diet before completing diagnostic testing, because doing so can normalize antibodies and gut appearance and make the diagnosis difficult to confirm. If celiac disease is confirmed, lifelong strict avoidance of gluten is the treatment, and you should be tested for related deficiencies (iron, vitamin D, vitamin B12, folate, calcium) and have your bone density assessed.